Coherus Oncology, Inc. (CHRS)Healthcare | Biotechnology | Redwood City, United States | NasdaqGM
1.82 USD
-0.17
(-8.543%) ⇩
(April 21, 2026, 4 p.m.
EDT)
After hours: 1.84 +0.02 (1.082%) ⇧ (April 21, 2026, 4:57 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:40 a.m. EDT
CHRS is currently exhibiting high-conviction bullish sentiment driven by厭scentist long-term growth narratives (65%+ revenue growth) and a supportive technical setup trading above key 50/200-day averages. The options chain clearly anticipates a move toward the $3.00 resistance level within the next 8-10 months, reflecting a 'soft bottom' at current levels and a high-conviction bet on catalyst-driven upside in the semiconductor/pharma space, despite the company's lack of profitability and recent capital raising efforts. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.247703 |
| AutoETS | 0.334786 |
| AutoTheta | 0.505326 |
| AutoARIMA | 0.717113 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 2.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.030 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.36 |
| Market Cap | 272,799,648 |
| Forward P/E | -2.25 |
| Beta | 1.04 |
| Profit Margins | 398.42% |
| Previous Name | Coherus BioSciences, Inc. |
| Website | https://www.coherus.com |
As of April 19, 2026, 1:40 a.m. EDT: Options activity is heavily skewed bullish. In the May and November expirations, Over-the-Money (OTM) Call Open Interest and Volume significantly outweigh Put activity. A distinct institutional flow is evident in the November 2026 E-Mini-style structure at the $3.00 strike (51% OTM positioning), where open interest matches call volume, creating a 'Top OI' wall. While ATM Call volume shows elevated new flow in November, the stark absence of Put volume outside the $1.50 strike confirms near-term pessimism is fully priced out of the playbook; speculators are positioning for a significant upside move.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8256881 |
| Address1 | 333 Twin Dolphin Drive |
| Address2 | Suite 600 |
| All Time High | 38.1 |
| All Time Low | 0.66 |
| Ask | 1.85 |
| Ask Size | 5 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,030,200 |
| Average Daily Volume3 Month | 2,148,319 |
| Average Volume | 2,148,319 |
| Average Volume10Days | 1,030,200 |
| Beta | 1.039 |
| Bid | 1.79 |
| Bid Size | 5 |
| Board Risk | 6 |
| Book Value | 0.504 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.82 |
| Current Ratio | 1.472 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.99 |
| Day Low | 1.81 |
| Display Name | Coherus BioSciences |
| Earnings Call Timestamp End | 1,773,088,200 |
| Earnings Call Timestamp Start | 1,773,088,200 |
| Earnings Timestamp | 1,773,086,400 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -172,510,000 |
| Ebitda Margins | 0.0 |
| Eps Current Year | -0.79 |
| Eps Forward | -0.81 |
| Eps Trailing Twelve Months | -1.56 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.747 |
| Fifty Day Average Change | 0.07300007 |
| Fifty Day Average Change Percent | 0.041785963 |
| Fifty Two Week Change Percent | 82.56881 |
| Fifty Two Week High | 2.616 |
| Fifty Two Week High Change | -0.7959999 |
| Fifty Two Week High Change Percent | -0.3042813 |
| Fifty Two Week Low | 0.71 |
| Fifty Two Week Low Change | 1.1100001 |
| Fifty Two Week Low Change Percent | 1.5633805 |
| Fifty Two Week Range | 0.71 - 2.616 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,284,200,000 |
| Float Shares | 134,686,569 |
| Forward Eps | -0.81 |
| Forward P E | -2.2469137 |
| Free Cashflow | -68,722,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 147 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.67244005 |
| Gross Profits | 28,358,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14974 |
| Held Percent Institutions | 0.34652 |
| Implied Shares Outstanding | 149,889,902 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California. |
| Long Name | Coherus Oncology, Inc. |
| Market | us_market |
| Market Cap | 272,799,648 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_206928583 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -183,124,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 298,280,904 |
| Number Of Analyst Opinions | 4 |
| Open | 1.98 |
| Operating Cashflow | -138,512,992 |
| Operating Margins | -4.18368 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 650 649 3530 |
| Post Market Change | 0.019699931 |
| Post Market Change Percent | 1.0824138 |
| Post Market Price | 1.8397 |
| Post Market Time | 1,776,805,037 |
| Prev Name | Coherus BioSciences, Inc. |
| Previous Close | 1.99 |
| Price Eps Current Year | -2.3037975 |
| Price Hint | 4 |
| Price To Book | 3.6111112 |
| Price To Sales Trailing12 Months | 6.4687386 |
| Profit Margins | 3.9842498 |
| Quick Ratio | 1.357 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.16999996 |
| Regular Market Change Percent | -8.542711 |
| Regular Market Day High | 1.99 |
| Regular Market Day Low | 1.81 |
| Regular Market Day Range | 1.81 - 1.99 |
| Regular Market Open | 1.98 |
| Regular Market Previous Close | 1.99 |
| Regular Market Price | 1.82 |
| Regular Market Time | 1,776,801,601 |
| Regular Market Volume | 1,937,652 |
| Return On Assets | -0.312 |
| Revenue Per Share | 0.36 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 149,889,902 |
| Shares Percent Shares Out | 0.1878 |
| Shares Short | 28,142,006 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 27,657,585 |
| Short Name | Coherus Oncology, Inc. |
| Short Percent Of Float | 0.1935 |
| Short Ratio | 19.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | CHRS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.75 |
| Target Median Price | 6.5 |
| Total Revenue | 42,172,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.471495 |
| Two Hundred Day Average Change | 0.34850502 |
| Two Hundred Day Average Change Percent | 0.23683737 |
| Type Disp | Equity |
| Volume | 1,937,652 |
| Website | https://www.coherus.com |
| Zip | 94,065 |